Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Apr 14, 2016; 22(14): 3803-3812
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3803
Figure 4
Figure 4 Overall survival rate of the low-dose hepatocellular carcinoma group and high-dose hepatocellular carcinoma group after adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (A) and did not meet the Milan criteria (B). HBIG: Hepatitis B Immunoglobulin.